Valuation: Exelixis, Inc.

Market Cap 14.06B 12.28B 11.33B 10.45B 19.69B 1,354B 20.13B 135B 53.29B 663B 52.79B 51.63B 2,282B P/E 2026 *
17.6x
P/E 2027 * 15x
Enterprise Value 13.28B 11.61B 10.71B 9.87B 18.61B 1,279B 19.02B 128B 50.35B 626B 49.88B 48.79B 2,157B EV / Sales 2026 *
5.11x
EV / Sales 2027 * 4.21x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day+0.43%
1 week-1.03%
Current month+2.78%
1 month+7.72%
3 months+24.57%
6 months+27.21%
Current year+27.58%
1 week 54.39
Extreme 54.3928
56.75
1 month 50.8
Extreme 50.8
57.57
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 8.47
Extreme 8.4701
57.57
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap.
01/06/26 Sell

Director

-3,925 0.0016%
01/06/26 Sell

Director

-9,812 0.0039%
27/05/26 Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%-1.03%+25.75%+186.18% 14.06B
+0.24%-1.54%+52.85%+60.31% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+2.43%+1.34%+35.07%-6.50% 19.36B
-1.14%+0.03%+31.67%-31.21% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+4.13%-0.20%+33.21%+642.44% 14.83B
+1.46%+3.13%+65.65%+155.34% 12.76B
Average -0.49%-2.05%+44.41%+176.84% 24.63B
Weighted average by Cap. -1.31%-2.07%+41.82%+139.22%

Financials

2026 *2027 *
Net sales 2.6B 2.27B 2.1B 1.93B 3.64B 250B 3.72B 25.06B 9.86B 123B 9.76B 9.55B 422B 2.93B 2.56B 2.36B 2.18B 4.11B 282B 4.2B 28.25B 11.11B 138B 11.01B 10.76B 476B
Net income 819M 715M 660M 609M 1.15B 78.84B 1.17B 7.89B 3.1B 38.61B 3.07B 3.01B 133B 945M 826M 762M 703M 1.32B 91.05B 1.35B 9.11B 3.58B 44.59B 3.55B 3.47B 154B
Net Debt -774M -676M -624M -575M -1.08B -74.51B -1.11B -7.46B -2.93B -36.49B -2.91B -2.84B -126B -1.72B -1.5B -1.38B -1.28B -2.4B -165B -2.46B -16.54B -6.51B -80.94B -6.44B -6.3B -279B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
17/07/26 $55.92 +0.43% 2,555,561
16/07/26 $55.68 +0.23% 2,031,019
15/07/26 $55.55 -0.39% 1,895,909
14/07/26 $55.77 -0.48% 1,799,548
13/07/26 $56.04 -0.81% 2,844,304
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
55.92USD
Average target price
50.93USD
Spread / Average Target
-8.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock